Lutris Pharma CEO Dr Noa Shelach talked with Proactive's Stephen Gunnion about the company's innovative approach to enhancing cancer treatment adherence through its lead asset, LUT014. The clinical-stage biopharmaceutical company, founded in 2016, aims to improve the effectiveness of anti-cancer therapies and patient quality of life by addressing severe dermatological side effects such as acneiform lesions, a common adverse reaction to EGF receptor inhibitors. Shelach highlighted LUT014, a proprietary topical B-Raf inhibitor, designed to reduce dermal toxicities and improve treatment continuity. The company recently completed enrollment of 117 patients in a Phase 2 international trial for metastatic colorectal cancer, with promising results from a smaller Phase 1/2 study in breast cancer patients. However, the latter is not being actively pursued further. In January 2025, Lutris Pharma secured $30 million in financing, led by Columbus Venture Partners and Pontifex Venture Capital, alongside Peregrine Ventures and Moon Fund. The funds will support advancing LUT014 through Phase 3 development, aiming for commercialization to help cancer patients maintain their treatment regimens. Shelach noted the $1 billion market potential for LUT014, emphasizing that increased patient adherence to EGF receptor inhibitors could boost drug sales by 30%. Investors should watch for Phase 2 trial results expected in the first half of 2025, with Phase 3 trials planned to start by the end of the year. Stay tuned to Proactive’s YouTube channel for more interviews with industry leaders. Don't forget to like, subscribe, and hit the notification bell to keep up with the latest insights. #LutrisPharma #CancerTreatment #EGFRInhibitors #LUT014 #Biopharma #ClinicalTrials #Oncology #Investing #DermalToxicity #ColorectalCancer